Nutrition, Metabolism & Cardiovascular Diseases
Volume 19, Issue 7 , Pages 451-454 , September 2009

How to improve cardiovascular diseases prevention in Europe?

  • Ž. Reiner

      Affiliations

    • Corresponding Author InformationTel.: +385 1 49 200 19; fax: +385 1 48 18 457.

Received 7 April 2009

References 

  1. Allender S, Scarborough P, Peto V, Rayner M, Leal J, Luengo-Fernendaz R, et al. European cardiovascular disease statistics – 2008 edition. Brussels: European Heart Network; 2008;
  2. Lopez A, Mathers CD, Ezzati M, Jamison DT, Murray CJ. Global and regional burden of disease and risk factors: systematic analysis of population health data. Lancet. 2006;367:1747–1757
  3. Leal J, Luengo-Fernández R, Gray A, Petersen S, Rayner M. Economic burden of cardiovascular diseases in the enlarged European Union. Eur Heart J. 2006;27:1610–1619
  4. Reiner Z, Tedeschi-Reiner E. Atherosclerosis – a paradox of Eastern European countries. Atherosclerosis. 2006;7/3(Suppl.):461
  5. Merkler M, Reiner Z. The burden of hyperlipidaemia and diabetes in cardiovascular diseases. Fundam Clin Pharmacol. 2007;21(Suppl. 2):1–3
  6. Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R, et al. European guidelines on cardiovascular disease prevention in clinical practice: full text. Eur J Cardiovasc Prev Rehabil. 2007;14(Suppl. 2):S1–S113
  7. Pyorala K, De Backer G, Graham I, Poole-Wilson P, Wood D. Prevention of coronary heart disease in clinical practice: recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Atherosclerosis. 1994;110:121–161
  8. Wood D, De Backer G, Faergeman O, Graham I, Mancia G, Pyorala K. Prevention of coronary heart disease in clinical practice. Recommendations of the second joint task force of European and other societies on coronary prevention. Eur Heart J. 1998;19:1434–1503
  9. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, et al. European guidelines on cardiovascular disease prevention in clinical practice. Eur J Cardiovasc Prev Rehabil. 2003;10(Suppl. 1):S1–S78
  10. Cholesterol Education Program (NCEP) Expert Panel on Detection . Evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). Final report. Circulation. 2002;106:3143–3421
  11. Reiner Z, Mihatov Š, Miličić D, Bergovec M, Planinc D. Treatment and secondary prevention of ischemic coronary events in Croatia (TASPIC-CRO study). Eur J Cardiovasc Prev Rehabil. 2006;13:636–654
  12. EUROASPIRE Study Group . EUROASPIRE: a European Society of Cardiology survey of secondary prevention of coronary heart disease: principal results. Eur Heart J. 1997;18:1569–1582
  13. EUROASPIRE II Group . Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries: principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J. 2001;22:554–572
  14. Prugger C, Heidrich J, Amouyel P, De Backer G, De Bacquer D, Jennings C, et al. Time trends in blood pressure levels in coronary patients across the Europe: the EUROASPIRE study. Eur Heart J. 2008;29(Abstract Suppl.):695
  15. Heidrich J, Prugger C, De Backer G, De Bacquer D, Gaita D, Jennings C, et al. Smoking cessation after hospitalization for coronary heart disease across Europe. Results of the EUROASPIRE III study. Eur Heart J. 2008;29(Abstract Suppl.):699
  16. Dallongeville J, De Bacquer D, Heidrich J, Reiner Z, Amouyel P, De Backer G, et al. The challenge facing the care of diabetic coronary patients in Europe: the EUROASPIRE study. Eur Heart J. 2008;29(Abstract Suppl.):11–12
  17. Reiner Z, Amouyel P, De Bacquer D, De Backer G, Gaita D, Jennings C, et al. Treatment of dyslipidaemia in coronary patients in Europe: improving but still inadequate. Eur Heart J. 2008;29(Abstract Suppl.):761–762
  18. Poli A, Marangoni F, Paoletti R, Mannarino E, Lupattelli G, Notarbartolo A, et al. Non-pharmacological control of plasma cholesterol levels. Nutr Metab Cardiovasc Dis. 2008;18:S1–16
  19. Ho PM, Magid DJ, Shetterly SM, Olson KL, Peterson PN, Masoudi FA, et al. Importance of therapy intensification and medication nonadherence for blood pressure control in patients with coronary disease. Arch Intern Med. 2008;168:271–276
  20. Bergman Marković B, Kranjčević K, Reiner Z, Milaković Blažković S, Stojanović Špehar S. Drug therapy of cardiovascular risk factors: guidelines versus reality in primary health care service. Croat Med J. 2005;46:984–989
  21. <www.heartcharter.eu>
  22. Cramer C, Haan MN, Galea S, Langa KM, Kalbfleisch . Use of statins and incidence of dementia and cognitive impairment without dementia in a cohort study. Neurology. 2008;71:344–350
  23. Reiner Z. Statins in heart failure – a failure?. Nutr Metab Cardiovasc Dis. 2008;18:397–401
  24. GISSI-HF Investigators . Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomized, double blind, placebo controlled trial. Lancet. 2008;372(9645):1231–1239
  25. Rossebo AB, Pedersen TR, Boman K, Brudi P, Chambers JB, Egstrup K, et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med. 2008;359:1343–1356
  26. Barter PJ, Gotto AM, LaRosa JC, Maroni J, Szarek M, Grundy SM, et al. For the Treating to New Targets Investigators HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med. 2007;357:1301–1310
  27. Miller M, Cannon CP, Murphy SA, Qin J, Ray KK, Braunwald E. PROVE-TIMI 22 Investigators. Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE-IT TIMI 22 trial. J Am Coll Cardiol. 2008;51:724–730
  28. Kearney PM, Blackwell PM, Collins R, Keech A, Simes J, Peto R, et al. Cholesterol Treatment Trialists' (CTT) Collaborators Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 2008;371:117–125
  29. Frikke-Schmidt R, Nordestgaard BG, Stene MC, et al. Association of loss-of-function mutations in the ABCA1 gene with high-density lipoprotein cholesterol levels and risk of ischemic heart disease. JAMA. 2008;299:2524–2532
  30. Fruchart J-C, Sacks F, Hermans MP, Assmann G, Brown VW, Ceska R, et al. The residual risk reduction initiative: a call to action to reduce residual vascular risk in dyslipidemic patients. A position paper by the Residual Risk Reduction Initiative (R3I). Diab Vasc Dis Res. 2008;4:319–335
  31. Ritchie SA, Connell JM. The link between abdominal obesity, metabolic syndrome and cardiovascular disease. Nutr Metab Cardiovasc Dis. 2007;17:319–326
  32. van der Steeg WA, Holme I, Boekholdt SM, Larsen ML, Lindahl C, Stroes ESG, et al. High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein AI: significance for cardiovascular risk: the IDEAL and EPIC-Norfolk studies. J Am Coll Cardiol. 2008;45:127–153
  33. Kontush A, Chapman MJ. Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidaemia, inflammation, and atherosclerosis. Pharmacol Rev. 2006;58:342–374
  34. Singh-Manoux A, Gimeno D, Kivimaki M, Brunner E, Marmot MG. Low HDL cholesterol is a risk factor for deficit and decline in memory in midlife. Arterioscler Thromb Vasc Biol. 2008;28:1556–1562
  35. Jakovljevic M, Reiner Z, Milicic D. Mental disorders, treatment response, mortality and serum cholesterol: a new holistic look at old data. Psychiatria Danubina. 2007;19:279–290
  36. Wood DA, Kotseva K, Connoly S, Jennings C, Mead A, Jones J, et al. EUROACTON Study Group Nurse-coordinated multidiciplinary, family based cardiovascular disease prevention programme (EUROACTION) for patients with coronary heart disease and asymptomatic individuals at high risk of cardiovascular disease: a paired, cluster-randomised controlled trial. Lancet. 2008;14(371):1999–2012
  37. Balducci S, Zanuso S, Massarini M, Corigliano G, Nicolucci A, Missori S, et al. The Italian Diabetes and Exercise Study: design and methods for a prospective Italian multicentre trial of intensive lifestyle intervention in the people with type 2 diabetes and the metabolic syndrome. Nutr Metab Cardiovasc Dis. 2008;18:585–595

PII: S0939-4753(09)00156-2

doi: 10.1016/j.numecd.2009.06.006

Nutrition, Metabolism & Cardiovascular Diseases
Volume 19, Issue 7 , Pages 451-454 , September 2009

Article Tools